One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Feasibility and acceptability of electronic administration of patient reported outcomes using mHealth platform in emergency department patients with non-medical opioid use
Kathryn Hawk, Caitlin Malicki, Jeremiah Kinsman, Gail D’Onofrio, Andrew Taylor & Arjun Venkatesh
doi : 10.1186/s13722-021-00276-0
Addiction Science & Clinical Practice volume 16, Article number: 66 (2021)
The emergency department (ED) offers an important opportunity to identify patients with opioid use disorder (OUD) and initiate treatment. However, post-ED follow-up is challenging, and novel approaches to enhance care transitions are urgently needed. Outcomes following ED visits have traditionally focused on overdose, treatment engagement, and mortality with an absence of patient reported outcomes (PROs), for example patient ability to schedule follow-up OUD treatment appointments or pick up a prescription medication, that may better inform evaluation of treatment pathways and near-term outcomes after acute events. In the context of increasing novel secure mobile health (mHealth) platforms, we explored the feasibility and acceptability of electronically collecting PROs from ED patients with non-medical opioid use to enhance care in the ED and transitions of care.
Perspectives on extended-release naltrexone induction among patients living with HIV and opioid use disorder: a qualitative analysis
Kim A. Hoffman, Robin Baker, Laura C. Fanucchi, Paula J. Lum, Lynn E. Kunkel, Javier Ponce Terashima, Dennis McCarty, Petra Jacobs & P. Todd Korthuis
doi : 10.1186/s13722-021-00277-z
Addiction Science & Clinical Practice volume 16, Article number: 67 (2021)
The CHOICES study randomized participants with HIV and opioid use disorder (OUD) to HIV clinic-based extended-release naltrexone (XR-NTX), which requires complete cessation of opioid use, versus treatment-as-usual (i.e., buprenorphine, methadone). Study participants randomized to XR-NTX were interviewed to assess their experiences with successful and unsuccessful XR-NTX induction.
Early innovations in opioid use disorder treatment and harm reduction during the COVID-19 pandemic: a scoping review
Noa Krawczyk, Adetayo Fawole, Jenny Yang & Babak Tofighi
doi : 10.1186/s13722-021-00275-1
Addiction Science & Clinical Practice volume 16, Article number: 68 (2021)
The COVID-19 pandemic has exerted a significant toll on the lives of people who use opioids (PWUOs). At the same time, more flexible regulations around provision of opioid use disorder (OUD) services have led to new opportunities for facilitating access to services for PWUOs. In the current scoping review, we describe new services and service modifications implemented by treatment and harm reduction programs serving PWUO, and discuss implications for policy and practice.
The validation and reliability of a Japanese version of the Problematic Online Gaming Questionnaire (POGQ-J)
Kazuya Inoue, Kengo Yokomitsu, Tomonari Irie, Makoto Matsuyama & Masanori Tanaka
doi : 10.1186/s13722-021-00273-3
Addiction Science & Clinical Practice volume 16, Article number: 69 (2021)
The Problematic Online Gaming Questionnaire (POGQ) is an 18-item self-rated measure designed to assess the degree of problematic online gaming. This study translated the POGQ into Japanese (POGQ-J) and examined the POGQ-J’s factor structure, validity, and reliability for a Japanese population.
A systematic review of GWAS identified SNPs associated with outcomes of medications for opioid use disorder
Caroul Chawar, Alannah Hillmer, Stephanie Sanger, Alessia D’Elia, Balpreet Panesar, Lucy Guan, Dave Xiaofei Xie, Nandini Bansal, Aamna Abdullah, Flavio Kapczinski, Guillaume Pare, Lehana Thabane & Zainab Samaan
doi : 10.1186/s13722-021-00278-y
Addiction Science & Clinical Practice volume 16, Article number: 70 (2021)
Patients with opioid use disorder (OUD) display an interindividual variability in their response to medications for opioid use disorder (MOUD). A genetic basis may explain the variability in this response. However, no consensus has been reached regarding which genetic variants significantly contribute to MOUD outcomes.
